PMPRB finds ultra-rare drug PROCYSBI is excessively priced | Smart & Biggar
On September 1, 2022, a Panel of the Patented Medicine Prices Review Board (PMPRB) issued a decision that the price of Horizon Pharma’s PROCYSBI (cysteamine delayed release capsules)...
Source: jdsupra.com